Accuracy of IOP measurements questioned

Article

Dynamic contour tonometry (DCT) may be more accurate than Goldmann applanation tonometry (GAT) in measuring intraocular pressure (IOP), according to study results published in the February issue of Eye.

Dynamic contour tonometry (DCT) may be more accurate than Goldmann applanation tonometry (GAT) in measuring intraocular pressure (IOP), according to study results published in the February issue of Eye.

Pierre Ceruti of the Borgo Trento Hospital at the University of Verona, Italy and colleagues used DCT and GAT to measure IOP in healthy eyes (n=100), eyes with primary open angle glaucoma (n=100) and eyes with primary angle closure glaucoma (n=100). The team also noted the age of patients, measured corneal thickness (CCT) and curvature (CC), and axial length (AL), and then conducted regression analysis to evaluate the impact these metrics exerted on each of the measurement techniques.

The IOP values measured by DCT were 2.6±1.9 mmHg higher when compared with GAT measurements, and the degree of difference increased proportionally with CCT. With both increasing CCT and IOP, however, the degree of difference between the measurements reduced. DCT measurements were not affected by CCT, although GAT measurements were. CC, AL and age did not impact on readings with either instrument.

The team concluded that the degree of difference in measurement was higher in healthy eyes than in glaucomatous eyes; overall, GAT measurements were more affected by CCT and measured lower IOP readings when compared with DCT.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.